In recent years, few AD drug discoveryprograms have focused ondual Aβ/Tau inhibitors, able to interfere with protein–proteininteractions (PPIs), to avoid propagation, or to prevent fibril formation.However, not many of these inhibitors were purposely designed to targetAβ and Tau aggregation simultaneously; most of the reports focusedon acetylcholinesterase (AChE) inhibitors where Aβ and Tau antiaggregationwas an activity designed-in by random screening. The gene discussed is MAPT; the disease is Alzheimer disease.